Tempus AI is trading 4.1% down at $77.08, with no clear negative company-specific catalyst identified for September 18, 2026.

  • The decline follows a sharp recent rally, including a 14.85% gain on September 17.
  • Recent coverage remains broadly constructive, citing Merck and Moderna sequencing work and ongoing analyst interest.
  • The broader market is only modestly lower; profit-taking or positioning may be factors, but causation remains unconfirmed.